Related references
Note: Only part of the references are listed.Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity
Chantal Stoepker et al.
DNA REPAIR (2015)
Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis
Cezary Cybulski et al.
LANCET ONCOLOGY (2015)
FANCI Regulates Recruitment of the FA Core Complex at Sites of DNA Damage Independently of FANCD2
Maria Castella et al.
PLoS Genetics (2015)
Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer
Anna Tervasmaki et al.
BMC CANCER (2014)
Breast-Cancer Risk in Families with Mutations in PALB2
A. C. Antoniou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer
Johanna I. Kiiski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer
R. Fagerholm et al.
ANNALS OF ONCOLOGY (2013)
Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4
Yonghwan Kim et al.
BLOOD (2013)
Genetic Susceptibility to Triple-Negative Breast Cancer
Kristen N. Stevens et al.
CANCER RESEARCH (2013)
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Ahrum Min et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Fanconi anaemia and the repair of Watson and Crick DNA crosslinks
Molly C. Kottemann et al.
NATURE (2013)
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
Mike De Vos et al.
BIOCHEMICAL PHARMACOLOGY (2012)
The DNA translocase activity of FANCM protects stalled replication forks
Andrew N. Blackford et al.
HUMAN MOLECULAR GENETICS (2012)
CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer
Maren Weischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility
Mikko Vuorela et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
ST14 Gene Variant and Decreased Matriptase Protein Expression Predict Poor Breast Cancer Survival
Jaana M. Kauppinen et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
FANCM regulates DNA chain elongation and is stabilized by S-phase checkpoint signalling
Sarah Luke-Glaser et al.
EMBO JOURNAL (2010)
ATR activation and replication fork restart are defective in FANCM-deficient cells
Rebekka A. Schwab et al.
EMBO JOURNAL (2010)
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
Remi Buisson et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype
Tuomas Heikkinen et al.
CLINICAL CANCER RESEARCH (2009)
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
Helen E. Bryant et al.
EMBO JOURNAL (2009)
FANCM Connects the Genome Instability Disorders Bloom's Syndrome and Fanconi Anemia
Andrew J. Deans et al.
MOLECULAR CELL (2009)
FANCM and FAAP24 Function in ATR-Mediated Checkpoint Signaling Independently of the Fanconi Anemia Core Complex
Spencer J. Collis et al.
MOLECULAR CELL (2008)
NAD(P)H:quinone oxidoreductase 1 NQO1☆2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer
Rainer Fagerholm et al.
NATURE GENETICS (2008)
Molecular Origins of Cancer: Inherited Susceptibility to Common Cancers
William D. Foulkes
NEW ENGLAND JOURNAL OF MEDICINE (2008)
An oncogene-induced DNA damage model for cancer development
Thanos D. Halazonetis et al.
SCIENCE (2008)
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer
J. Tommiska et al.
ONCOGENE (2008)
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation
Marjanka K. Schmidt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Breast cancer patients with p53 pro72 homozygous genotype have a poorer survival
J Tommiska et al.
CLINICAL CANCER RESEARCH (2005)
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
J Bartkova et al.
NATURE (2005)
Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients
O Kilpivaara et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD(+) into a nuclear signal
MY Kim et al.
GENES & DEVELOPMENT (2005)
Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
H Eerola et al.
BREAST CANCER RESEARCH (2005)
Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks
YG Yang et al.
ONCOGENE (2004)
A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome
AR Meetei et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer
P Vahteristo et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients
L Sarantaus et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2001)
A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families
P Vahteristo et al.
BRITISH JOURNAL OF CANCER (2001)
Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients
K Syrjäkoski et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Familial breast cancer in southern Finland:: how prevalent are breast cancer families and can we trust the family history reported by patients?
H Eerola et al.
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
